Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.15    -0.005 (-3.23%)
Bid:
0.14
Ask:
0.16
Spread: 0.02 (14.286%)
Market Cap: £1.98m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Final Results

29 Jun 2006 12:20

Azure Holdings PLC29 June 2006 Azure Holdings plc REPORT AND FINANCIAL STATEMENTS For the year ended 31 December 2005 CHAIRMAN'S STATEMENT I am pleased to present my first Chairman's statement for the year ended 31December 2005. In the year to 31 December 2005 the Company announced a loss after taxation of£134,000 (2005: £345,000). My predecessor mentioned in his last Chairman's statement that the Company wascontinuing to seek an acquisition and I am pleased we have a target and that thetransaction is moving forward. Your Company not only has a new Board but also a new Nominated Adviser andBroker and we are all working together to bring the proposed transaction to amutually satisfactory conclusion. All parties are aware of the need to complete the transaction by the end ofSeptember and at the time of writing we remain on target to do so. Barry Gold Chairman 29 June 2006 AZURE HOLDINGS PLC PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2005 2005 2004 Note Total Total £'000 £'000 Administrative expenses (134) (345) OPERATING LOSS (134) (345) LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION (134) (345) Taxation - - LOSS ON ORDINARY ACTIVITIES AFTER TAXATION (134) (345) LOSS PER SHARE 3 (0.28p) (0.86p) FULLY DILUTED LOSS PER SHARE 3 (0.28p) (0.86p) The Company has no recognised gains or losses other than the loss for the year. All activities are classed as continuing. AZURE HOLDINGS PLC BALANCE SHEET AT 31 DECEMBER 2005 2005 2004 £'000 £'000 CURRENT ASSETSDebtors 1 7Cash at bank and in hand 1 14 2 21CREDITORS: amounts falling due within one year (205) (90) NET CURRENT LIABILITIES (203) (69) TOTAL ASSETS LESS CURRENT LIABILITIES (203) (69) CAPITAL AND RESERVES Called up share capital 5,475 5,475Share premium account 10,279 10,279Profit and loss account (15,957) (15,823) EQUITY SHAREHOLDERS' FUNDS (203) (69) AZURE HOLDINGS PLC CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2005 2005 2004 £'000 £'000 CASH OUTFLOW FROM OPERATING ACTIVITIES (63) (225) FINANCING Issue of equity shares - 120Loans 50 - DECREASE IN CASH IN THE YEAR (13) (105) AZURE HOLDINGS PLC NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2005 1. Basis of preparation The financial information in this announcement does not constitute statutory financial statements as defined in Section 240 of the Companies Act 1985. The information relating to the year ended 31 December 2004 is an extract from the statutory accounts for that year, which have been delivered to the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statements under section 237(2) or (3) of the Companies Act 1985. The auditors have indicated that they will issue an unqualified report on the statutory financial statements for the year ended 31 December 2005. Copies of the Company's Report and Financial Statements will be despatched to shareholders on 29 June 2006 and will be available at the registered office of the Company: One Great Cumberland Place, London W1H 7AL. 2. Going Concern The financial statements have been prepared on the going concern basis. During the year the company incurred a loss of £134,000 and had net liabilities at 31 December 2005 of £203,000. Since the year end, the company has raised £398,000 via the issue of convertible loan stock. The directors continue to actively seek a suitable target for a reverse acquisition. The directors have therefore prepared the financial statements on the going concern basis. The financial statements do not include any adjustments that might arise if this basis was inappropriate. 3. Loss per share Loss per share are calculated using the loss on ordinary activities and the weighted average number of shares detailed below. In calculating fully diluted loss per share, the weighted average number of shares is adjusted for the effect of dilutive share options issued under Company share option schemes. 2005 2004 £'000 £'000 Basic and diluted loss attributable to ordinary (134) (345) shareholders Number Number Weighted average number of ordinary shares 48,317,569 39,767,965 Dilutive share options - - Adjusted weighted average number of ordinary 48,317,569 39,767,965 shares Loss per share (0.28p) (0.86p) Fully diluted loss per share (0.28p) (0.86p) 4. Reconciliation of Operating Loss to Net Cash 2005 2004 Outflow from Operating Activities £'000 £'000 Operating Loss (134) (345) Decrease in debtors 6 - Increase in creditors 65 31 Creditor settled via issue of shares - 89 Net cash outflow from operating activities (63) (225) 5. Reserves Share premium Profit and loss Total account account £'000 £'000 £'000 At 1 January 2005 10,279 (15,823) (5,544) Loss for the year (134) (134) At 31 December 2005 10,279 (15,957) (5,678) 6. Taxation Factors affecting taxation: The tax charge for the year does not equate to the loss before tax at the standard rate of corporation tax in the United Kingdom (30%). The differences are explained below: 2005 2004 £'000 £'000 Loss on ordinary activities before taxation (134) (345) Loss on ordinary activities multiplied by the (40) (104) standard rate of corporation tax in the United Kingdom of 30% (2004:30%) Effect of non-deductible expenses and addition 40 104 to tax losses As 31 December 2005, the Company had accumulated tax losses of £950,000 (2004:£817,000) arising from management expenses and £1,477,000) of capital losses. A deferred tax asset has not been recognised in respect of these losses as they are not expected to be used in the foreseeable future. 7. Dividends The directors are not proposing the payment of a dividend in respect of the year ended 31 December 2005. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Oct 20147:00 amRNSTotal Voting Rights
23rd Oct 201410:45 amRNSGrant of options
14th Oct 20147:00 amRNSApproved Clinical Trial Update
8th Oct 20144:12 pmRNSEarly Completion of Equity Swap Agreement
8th Oct 20144:08 pmRNSHolding(s) in Company
2nd Sep 20147:00 amRNSValiSeek Development Update
28th Aug 201411:33 amRNSHolding(s) in Company
19th Aug 20147:00 amRNSHalf Yearly Report
5th Aug 201412:05 pmRNSHolding(s) in Company
4th Aug 20147:00 amRNSNotice of Acceptance of CTA Request
1st Jul 201411:35 amRNSHolding(s) in Company
24th Jun 20147:00 amRNSDirector/PDMR Shareholding
18th Jun 20149:22 amRNSNew Corporate Website & New Office Address
10th Jun 20147:00 amRNSSubmission of Clinical Trial Application re VAL201
15th May 20147:00 amRNSValiSeek Development Update
1st May 20147:00 amRNSNew Japanese Patent Grant
23rd Apr 20144:29 pmRNSResult of AGM
17th Apr 20145:51 pmRNSHolding(s) in Company
8th Apr 20147:00 amRNSValiSeek Joint Venture
1st Apr 20147:00 amRNSVAL201 Update
31st Mar 20144:45 pmRNSNotice of AGM
31st Mar 20144:09 pmRNSHolding(s) in Company
28th Mar 20147:01 amRNSPosting of R&As and Notice of AGM
19th Mar 20147:00 amRNSFinal Results
20th Feb 20147:00 amRNSNew European Patent Grant
31st Jan 201412:45 pmRNSSale of shares in VolitionRx
22nd Jan 20143:00 pmRNSGrant of Options
16th Jan 20147:00 amRNSIssue of Equity
27th Dec 20137:00 amRNSFundraising and Equity Swap
5th Dec 20137:00 amRNSNew Australian Patent Grant
28th Nov 20137:00 amRNSUpdate re Positive VAL201 & Biomarker Unit Studies
15th Nov 20137:00 amRNSPlacing to raise £1m
1st Nov 20137:00 amRNSChange of Broker
24th Oct 20134:25 pmRNSRe: VAL201 - Update
8th Oct 20137:00 amRNSDirectorate Changes
5th Sep 20137:00 amRNSHalf Yearly Report
15th Aug 20137:00 amRNSConsortium incl. ValiRx Awarded Eurostars Grant
31st Jul 20137:00 amRNSUpdate
25th Jun 20137:00 amRNSInvestor Presentation in Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
13th Jun 20137:00 amRNSRe: VAL201 Update
6th Jun 201310:00 amRNSValiRx admitted as founder member of the SSE
25th Apr 20137:00 amRNSNew Patent Granted
22nd Apr 201311:52 amRNSResult of AGM
2nd Apr 20137:00 amRNSUpdate on Developmental and Clinical Activity
28th Mar 20137:01 amRNSFinal Results
21st Feb 20137:00 amRNSRe Commercial Development Update
23rd Jan 20137:00 amRNSAppointment of Medical Monitoring Officer
31st Dec 20127:00 amRNSTotal Voting Rights
22nd Nov 20127:00 amRNSRe: Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.